Facts and Spin, page-22

I have finally got up off the floor after yesterdays news. No doubt the SPL management were blind sided by the FDA. Only time will tell (and we may never know) if the FDA questions are fair and should have been foreseen by SPL or if the goal posts moved due to internal FDA changes or external business 'influences'.

But we should not forget the positives and make our call on the underlying value of SPL and decide if its time to fold or double up (I am of the latter inclination). We have plenty of cash, an exciting DEP dendrimer platform (which is the real prize after all) and some revenue will come in 2019 from the ROW licences for Vivagel (assuming the imminent launches do proceed). I also believe Vivagel will be sold in the US and become a significant revenue generator but just not this year.

Does this setback warrant the 40% reduction in the value of SPL? I think not and am putting my money where my mouth is! Anyone else? ;-)